Reference scaled BE - FDA (and FARTSSIE update) [RSABE / ABEL]

posted by KR – India, 2010-04-27 15:14 (5893 d 16:16 ago) – Posting: # 5246
Views: 41,809

Dear Dave,

It is really a valuable and appreciable work done. Thanks.

However, in "Bioequivalence, Replicate" sheet, I have one concern: FDA recommends 3 period, 3 sequence crossover study but there is only one option of 3 period, 2 sequence (ABB/BAA) in the excel sheet which is not matching with the sequences given in the FDA recommendation. So in this case,the sample size calculated from the xls sheet and the sample size required for FDA recommended reference scaled study will remain the same ? Same case is for 4 period replicate study also.

Kindly provide your valuable comment on the same.

Thanks once again.

KR


Edit: Full quote removed (like in almost all your replies). Please delete anything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Jaime]

Complete thread:

UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
151 visitors (0 registered, 151 guests [including 22 identified bots]).
Forum time: 07:31 CEST (Europe/Vienna)

Always listen to experts.
They’ll tell you what can’t be done and why.
Then do it.    Robert A. Heinlein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5